Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totalling 54,200 shares, a decrease of 8.9% from the September 15th total of 59,500 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 17,700 shares, the days-to-cover ratio is presently 3.1 days.
Avalo Therapeutics Stock Up 4.3 %
Shares of NASDAQ:AVTX opened at $9.69 on Wednesday. The company has a 50-day moving average price of $9.19 and a 200 day moving average price of $11.43. Avalo Therapeutics has a 12 month low of $3.95 and a 12 month high of $42.34.
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($14.07) EPS for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Research analysts expect that Avalo Therapeutics will post -7.78 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Avalo Therapeutics
Avalo Therapeutics Company Profile
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Read More
- Five stocks we like better than Avalo Therapeutics
- The How and Why of Investing in Gold Stocks
- Bank of America Earnings Uncover Shifts in Consumer Spending
- Insider Trading – What You Need to Know
- NVIDIA Stock Continues to Be Wall Street’s Favorite: Here’s Why
- What Are Dividend Challengers?
- Cavco’s Future Looks Bright as Affordable Housing Demand Soars
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.